Seer, Inc. Class A (SEER)

Over the past six months, Seer's stock price has been impacted by several events. In November 2025, Seer reported its third-quarter financial results, with revenue up 2% year-over-year, and noted increased instrument shipments. A Nature Genetics study validated Seer's Proteograph platform. In February 2026, a shareholder, Radoff-JEC Group, called for governance and operational changes due to a share price decline. Seer adopted a tax benefit preservation plan. The company's fourth-quarter and full-year 2025 financial results showed growth in instrument installed base and consumable kit volume, but Q4 revenue missed analyst expectations, leading to a stock decline. The company's 2026 revenue guidance also contributed to a negative market reaction. Overall, the stock price has decreased by 7.50% over the last six months.

The provided information does not explicitly indicate a strong demand seasonality for Seer, Inc.'s products and services. The company's financial results have been impacted by external factors such as delayed NIH funding and cautious customer spending, and its 2026 guidance reflects ongoing funding uncertainty. Seer has implemented strategies like the Strategic Instrument Placement Program (SIPP) and its Seer Technology Access Center (STAC) to manage and stimulate demand.

Seer, Inc. (NASDAQ: SEER) is an American biotechnology company established in 2017 and headquartered in Redwood City, California. It operates within the Healthcare sector and Biotechnology industry, focusing on developing technologies for proteomics research. Seer's core business involves decoding the biology of the proteome through its Proteograph Product Suite, which includes engineered nanoparticles, consumables, automation instrumentation, and data analysis software. The company offers products like the Proteograph RISE, XT, and ONE Assay kits for deep, unbiased proteomic analysis and provides proteomics services through its Seer Technology Access Centers (STAC) in Redwood City and Bonn, Germany. Seer's products are marketed for research use only to academic institutions, life sciences and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.

Seer, Inc. is headquartered in Redwood City, California, with an additional office in San Diego, California, and a services laboratory in Bonn, Germany. The company has a global presence with sales and customer support staff located in the USA, Europe, and Asia. Its operational and market reach extends to countries including China, Australia, Eastern Europe, Israel, Japan, and South Africa.

Seer, Inc. strengthened its brand reputation through scientific validation and increased technology adoption, with publications utilizing Seer's technology nearly doubling by the end of 2025 and a strong presence at the 2025 HUPO World Congress. A Nature Genetics study in November 2025 validated the Proteograph platform. However, the company's reputation faced challenges in February 2026 when a shareholder publicly criticized the company's governance and operational performance, and the Q4 2025 revenue miss and subsequent stock decline could negatively impact investor confidence.

Major institutional owners of Seer, Inc. include SoftBank Group Corp, Invus Public Equities, L.P., aMoon Growth Fund II, L.P., The Vanguard Group, Inc., BlackRock, Inc., Acadian Asset Management LLC, Renaissance Technologies LLC, Nano-Cap New Millennium Advisors, Llc, State Street Corp, Invesco Ltd., Corient Private Wealth LLC, Quadrature Capital Ltd, Millennium Management LLC, Bridgeway Capital Management LLC, Royal Bank of Canada, Squarepoint Ops LLC, Barclays PLC, Marshall Wace LLP, Dimensional Fund Advisors LP, T3 Companies LLC, and Goldman Sachs Group Inc. Omid Farokhzad, the co-founder and CEO, is a significant individual owner.